Alpha-internexin and altered CIC expression as a supportive diagnostic marker for oligodendroglial tumors with the 1p/19q co-deletion
- PMID: 24197863
- DOI: 10.1007/s10014-013-0168-7
Alpha-internexin and altered CIC expression as a supportive diagnostic marker for oligodendroglial tumors with the 1p/19q co-deletion
Abstract
α-Internexin (INA) has been proposed as a biomarker of oligodendroglial tumors with the 1p/19q co-deletion. On the other hand, sequence studies have recently linked the CIC mutation and subsequent altered CIC expression to the 1p/19q co-deletion in oligodendroglial tumors. We assessed the usability of combination immunohistochemical analysis using CIC and INA as a surrogate tool for the 1p/19q status in 39 cases of oligodendroglial tumors. The positive expression of INA was observed in 10 cases (52 %) of oligodendroglial tumors with the 1p/19q co-deletion, and in only 3 cases of oligodendroglial tumors without the 1p/19q co-deletion (15 %, P = 0.012). The lack of CIC expression was detected in 13 cases (68 %) of oligodendroglial tumors with the 1p/19q co-deletion, and in only 1 case of oligodendroglial tumors without the 1p/19q co-deletion (5 %, P < 0.0001). Combined immunohistochemical analysis assessed by INA expression and/or the lack of CIC expression was strongly associated with the 1p/19q co-deletion in oligodendroglial tumors, indicating a potential surrogate marker of the 1p/19q state. Although combined immunohistochemical analysis cannot be totally replaced by molecular genetic analysis as a definitive diagnostic technique, it may contribute to a steady morphological diagnosis by predicting the 1p/19q state in oligodendroglial tumors.
Similar articles
-
[Diagnostic and prognostic roles of loss of CIC protein expression in oligodendroglial tumors].Zhonghua Bing Li Xue Za Zhi. 2017 Oct 8;46(10):679-683. doi: 10.3760/cma.j.issn.0529-5807.2017.10.004. Zhonghua Bing Li Xue Za Zhi. 2017. PMID: 29050068 Chinese.
-
α-Internexin in the diagnosis of oligodendroglial tumors and association with 1p/19q status.J Neuropathol Exp Neurol. 2011 Nov;70(11):970-8. doi: 10.1097/NEN.0b013e3182333ef5. J Neuropathol Exp Neurol. 2011. PMID: 22002423
-
Loss of chromosome 1p/19q in oligodendroglial tumors: refinement of chromosomal critical regions and evaluation of internexin immunostaining as a surrogate marker.J Neuropathol Exp Neurol. 2011 Mar;70(3):177-82. doi: 10.1097/NEN.0b013e31820c765b. J Neuropathol Exp Neurol. 2011. PMID: 21293300
-
Clinicopathologic aspects of 1p/19q loss and the diagnosis of oligodendroglioma.Arch Pathol Lab Med. 2007 Feb;131(2):242-51. doi: 10.5858/2007-131-242-CAOQLA. Arch Pathol Lab Med. 2007. PMID: 17284109 Review.
-
Molecular background of oligodendroglioma: 1p/19q, IDH, TERT, CIC and FUBP1.CNS Oncol. 2015;4(5):287-94. doi: 10.2217/cns.15.32. Epub 2015 Nov 6. CNS Oncol. 2015. PMID: 26545048 Free PMC article. Review.
Cited by
-
Whole-Genome Sequence of the Metastatic PC3 and LNCaP Human Prostate Cancer Cell Lines.G3 (Bethesda). 2017 Jun 7;7(6):1731-1741. doi: 10.1534/g3.117.039909. G3 (Bethesda). 2017. PMID: 28413162 Free PMC article.
-
Signaling pathways in brain tumors and therapeutic interventions.Signal Transduct Target Ther. 2023 Jan 4;8(1):8. doi: 10.1038/s41392-022-01260-z. Signal Transduct Target Ther. 2023. PMID: 36596785 Free PMC article. Review.
-
Expression pattern of neuronal intermediate filament α-internexin in anterior pituitary gland and related tumors.Pituitary. 2015 Aug;18(4):465-73. doi: 10.1007/s11102-014-0597-2. Pituitary. 2015. PMID: 25236435
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous